AlphaStocks
5.3
Consider Buy

Regeneron Pharmaceuticals, Inc. (REGN)

As of Sep 18, 2026, Regeneron Pharmaceuticals, Inc. (REGN) scores 5.3/10 on AlphaStocks' five-model composite, #93 of 168 Health Care stocks. At $789, REGN trades 33% below its model fair value of $1,175.

Health Care / Biotechnology

S&P 500

$789.31

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 18, 2026

#93out of 168 in Health Care

Is REGENERON PHARMACEUTICALS, INC. a Good Investment in 2026?

REGENERON PHARMACEUTICALS, INC. (REGN) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates REGENERON PHARMACEUTICALS, INC. as Attractive (5/9). The Greenblatt Magic Formula model is the least favorable, rating it Neutral. REGENERON PHARMACEUTICALS, INC. currently trades 33% below its estimated fair value of $1,175. REGENERON PHARMACEUTICALS, INC. ranks #93 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E19.0ROE12.7Market Cap85BDiv Yield0.5

Estimated Fair Value

$1,175.1933% below

Trading below estimated fair value. P/E of 19x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

20% above fair value

Lynch

Attractive

PEG 1.0 · Fast Grower

Greenblatt

Neutral

Earnings yield 5.0% · ROC 10%

Frequently Asked Questions

Is REGENERON PHARMACEUTICALS, INC. (REGN) a good investment?
As of Sep 18, 2026, Regeneron Pharmaceuticals, Inc. (REGN) scores 5.3/10 on AlphaStocks' five-model composite, #93 of 168 Health Care stocks. At $789, REGN trades 33% below its model fair value of $1,175. That score is below average, suggesting caution.
What is REGENERON PHARMACEUTICALS, INC.'s Piotroski F-Score?
REGENERON PHARMACEUTICALS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is REGN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $1,175, REGN appears undervalued. The stock currently trades 33% below its estimated fair value. Trading below estimated fair value. P/E of 19x is moderate for this quality level.
How does REGN compare to other Health Care stocks?
REGENERON PHARMACEUTICALS, INC. ranks #93 out of 168 stocks in the Health Care sector, placing it in the top 55% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about REGN?
AlphaStocks evaluates REGN using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Neutral; Lynch: Attractive; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.3/10.

Similar Stocks

ABBVINCYHRMY

Compare REGN with

ABBV vs REGNINCY vs REGNHRMY vs REGN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer